Literature DB >> 17919948

Ubiquitin-mediated proteasomal degradation in normal and malignant hematopoiesis.

Mélina L Heuzé1, Isabelle Lamsoul, Christel Moog-Lutz, Pierre G Lutz.   

Abstract

Understanding the molecular mechanisms controlling normal hematopoietic differentiation is critical to develop new treatments for blood diseases and to manipulate stem cells. Despite the identification of many players in hematopoiesis, the molecular mechanisms controlling hematopoietic differentiation remain poorly understood. Due to a number of recent findings, the targeting of regulators of hematopoiesis to proteasomal degradation might be an important step in control of this developmental program.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17919948     DOI: 10.1016/j.bcmd.2007.07.011

Source DB:  PubMed          Journal:  Blood Cells Mol Dis        ISSN: 1079-9796            Impact factor:   3.039


  9 in total

1.  Identification of copy number alterations by array comparative genomic hybridization in patients with late chronic or accelerated phase chronic myeloid leukemia treated with imatinib mesylate.

Authors:  Veera S Nadarajan; Chin-Lee Phan; Chow-Hiang Ang; Kai-Ling Liang; Gin-Gin Gan; Ping-Chong Bee; Zubaidah Zakaria
Journal:  Int J Hematol       Date:  2011-03-09       Impact factor: 2.490

2.  Differential Degradation of TRA2A and PYCR2 Mediated by Ubiquitin E3 Ligase E4B.

Authors:  Yao Lu; Bo Jiang; Kangli Peng; Shasha Li; Xiangnan Liu; Bufan Wang; Yuntian Chen; Tiepeng Wang; Bo Zhao
Journal:  Front Cell Dev Biol       Date:  2022-05-20

Review 3.  Protacs for treatment of cancer.

Authors:  Kathleen M Sakamoto
Journal:  Pediatr Res       Date:  2010-05       Impact factor: 3.756

4.  ASB2 targets filamins A and B to proteasomal degradation.

Authors:  Mélina L Heuzé; Isabelle Lamsoul; Massimiliano Baldassarre; Yatish Lad; Sophie Lévêque; Ziba Razinia; Christel Moog-Lutz; David A Calderwood; Pierre G Lutz
Journal:  Blood       Date:  2008-09-17       Impact factor: 22.113

5.  NEDD4 Regulates PAX7 Levels Promoting Activation of the Differentiation Program in Skeletal Muscle Precursors.

Authors:  Francisco Bustos; Eduardo de la Vega; Felipe Cabezas; James Thompson; D D W Cornelison; Bradley B Olwin; John R Yates; Hugo C Olguín
Journal:  Stem Cells       Date:  2015-08-25       Impact factor: 6.277

6.  The ubiquitin conjugating enzyme, UbcM2, engages in novel interactions with components of cullin-3 based E3 ligases.

Authors:  Kendra S Plafker; Jeffrey D Singer; Scott M Plafker
Journal:  Biochemistry       Date:  2009-04-21       Impact factor: 3.162

7.  Silencing UBE4B induces nasopharyngeal carcinoma apoptosis through the activation of caspase3 and p53.

Authors:  Chengyin Weng; Yong Chen; Yong Wu; Xia Liu; Haibo Mao; Xisheng Fang; Baoxiu Li; Lina Wang; Mingmei Guan; Guolong Liu; Lin Lu; Yawei Yuan
Journal:  Onco Targets Ther       Date:  2019-04-08       Impact factor: 4.147

8.  The Roles of Ubiquitination Factor E4B (UBE4B) in the Postoperative Prognosis of Patients with Renal Cell Carcinoma and in Renal Tumor Cells Growth and Metastasis.

Authors:  Xu-Qiong Huang; Shuai Hao; Zi-Qi Zhou; Bin Huang; Jia-Ying Fang; Yan Tang; Jian-Hua Zhang; Jian-Chuan Xia
Journal:  Onco Targets Ther       Date:  2020-01-08       Impact factor: 4.147

9.  RING finger proteins are involved in the progression of barrett esophagus to esophageal adenocarcinoma: a preliminary study.

Authors:  Xing Wei Wang; Wei Wei; Wei Qiang Wang; Xiao Yan Zhao; Hong Guo; Dian Chun Fang
Journal:  Gut Liver       Date:  2014-02-24       Impact factor: 4.519

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.